Table 3 Effective half-lives of tumors and organs at risk determined using patient imaging data at {3 h, 24 h, 48 h},{3 h, 24 h}, {3 h, 48 h}, and {24 h, 48 h}. The data is compared to an effective half-life of 17 h (which would assume that AHDD-Lipiodol biological half-life is infinity, as in Zanzonico et al 2008 [29]). The data are presented as the average effective half-life across all patients ± SD in hours

From: Biodistribution, pharmacokinetics, and organ-level dosimetry for ¹⁸⁸Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans